Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of...
Medivation (MDVN +4.3%) continues to move higher today on the back of Friday's early approval of its prostate cancer drug Xtandi by the FDA. Wedbush says that ultimately Xtandi will surpass Zytiga in sales and the pre-chemotherapy data for the drug is going to make it the market leader.
From other sites
at Zacks.com (Thu, 3:20PM)
Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press Releasesat Zacks.com (Mar 18, 2015)
at Zacks.com (Feb 27, 2015)
at Zacks.com (Feb 26, 2015)
at Investor's Business Daily (Feb 26, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs